Drugs / Vabomere
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | VABOMERE | — | 2017-08-29 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02168946 | Jul 2014 → Jul 2017 | acute pyelonephritis, bacterial pneumonia, digestive system infectious disorder | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vabomere | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02168946 ↗ |
| Route | Intravenous | “Vabomere, (meropenem-vaborbactam) administered as a fixed combination by intravenous (IV) infusion” NCT02168946 ↗ |